Acta Clin Belg
-
The association of erythrocytosis and multiple myeloma is rare. We encountered a 76-year-old male patient with erythrocytosis followed by the diagnosis of multiple myeloma 8 months later. Related laboratory examinations revealed absolute erythrocytosis, normal oxygen saturation and erythropoietin (EPO) levels, the absence of endogenous erythroid colony (EEC) and JAK2-V617F mutations. ⋯ None of them is considered to be have idiopathic erythrocytosis. Our present case is the first one with multiple myeloma developing in a patient with the diagnosis well established by extensive laboratory workup. The pathogenic role of these two entities remains to be established.
-
In 2006, the International Conference of Experts on Intra-abdominal Hypertension defined abdominal perfusion pressure (APP) as the difference between mean arterial pressure (MAP) and intra-abdominal pressure (IAP).The aim of the study was to analyse changes in IAP and APP in patients undergoing elective coronary artery bypass grafting (CABG). ⋯ 1) The induction of anaesthesia decreased IAP. 2) ECC resulted in an increase in IAP. 3) IAP increased in 44% of patients. 4) IAP strongly correlated with BMI and central venous pressure. 5) CABG with ECC resulted in a decrease in APP. 6) Changes in APP strongly correlated with MAP and poorly correlated with other haemodynamic parameters. 7) The changes in APP demonstrated a double-phase character.
-
Sulfonylurea compounds are commonly used to treat type 2 diabetes mellitus. The case of an old alcoholic addicted diabetic patient treated with gliquidone developing recurrent and prolonged hypoglycaemias refractory to dextrose administration is related. According to the emergency literature, the use of octreotide in sulfonyurea-induced hypoglycaemia refractory to dextrose administration is related to overdoses of SUA. Use of octreotide with our patient allowed stabilization of the glycaemia.
-
Multicenter Study
90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study.
Severe sepsis is the major cause of mortality in intensive care units (ICUs). The BOOST study (= B (Belgian) OO (Open Label) ST (Study)) is a Belgian open-label trial designed to pragmatically assess the safety and efficacy of Drotrecogin Alfa (activated) (DAA), the only registered treatment in this indication with favourable ratio benefit/risk. ⋯ Despite a higher severity of illness at baseline, this phase IV open-label long-term study in Belgian ICUs shows consistent results with previous studies with DAA. Importantly, most of the surviving patients at day 90 were staying at home.
-
Recommendations, which aim at standardising and rationalising clinical indications for the transfusion of fresh frozen plasma (FFP) in Belgium, were drawn up by a working group of the Superior Health Council. For this purpose the Superior Health Council organised an expert meeting devoted to "Transfusion Guidelines: Pathogen reduction, products and indications for the transfusion of plasma" in collaboration with the Belgian Haematological Society. The experts discussed the indications for the transfusion of FFP, pathogen reduction for FFP and the practical issues of administering FFP and plasma-derived concentrates. The recommendations formulated by the experts were validated by the working group with the purpose of harmonising FFP transfusion in Belgian hospitals.